193 related articles for article (PubMed ID: 20373852)
21. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer.
Wadelius M; Autrup JL; Stubbins MJ; Andersson SO; Johansson JE; Wadelius C; Wolf CR; Autrup H; Rane A
Pharmacogenetics; 1999 Jun; 9(3):333-40. PubMed ID: 10471065
[TBL] [Abstract][Full Text] [Related]
22. Influence of GSTM1, GSTT1, GSTP1, NAT1, NAT2, EPHX1, MTR and MTHFR polymorphism on chromosomal aberration frequencies in human lymphocytes.
Skjelbred CF; Svendsen M; Haugan V; Eek AK; Clausen KO; Kure EH; Tuimala JT; Svendsen MV; Norppa H; Hansteen IL
Carcinogenesis; 2011 Mar; 32(3):399-405. PubMed ID: 21097530
[TBL] [Abstract][Full Text] [Related]
23. [The effect of polymorphism of genes of xenobiotics detoxication on the frequencies of spontaneous and induced chromosome aberrations in human lymphocytes].
Sal'nikova LE; Akaeva EA; Elisova TV; Kuznetsova GI; Kuz'mina NS; Vesnina IN; Lapteva NSh; Chumachenko AG; Romanchuk VA; Rubanovich AV
Radiats Biol Radioecol; 2009; 49(5):543-51. PubMed ID: 19947517
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.
Zand N; Tajik N; Moghaddam AS; Milanian I
Clin Exp Pharmacol Physiol; 2007; 34(1-2):102-5. PubMed ID: 17201743
[TBL] [Abstract][Full Text] [Related]
25. Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran.
Azarpira N; Namazi S; Hendijani F; Banan M; Darai M
Pharmacol Rep; 2010; 62(4):740-6. PubMed ID: 20885015
[TBL] [Abstract][Full Text] [Related]
26. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia.
Griese EU; Ilett KF; Kitteringham NR; Eichelbaum M; Powell H; Spargo RM; LeSouef PN; Musk AW; Minchin RF
Pharmacogenetics; 2001 Feb; 11(1):69-76. PubMed ID: 11207032
[TBL] [Abstract][Full Text] [Related]
27. Lack of association between human longevity and genetic polymorphisms in drug-metabolizing enzymes at the NAT2, GSTM1 and CYP2D6 loci.
Muiras ML; Verasdonck P; Cottet F; Schächter F
Hum Genet; 1998 May; 102(5):526-32. PubMed ID: 9654200
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility.
Chen HC; Hu WX; Liu QX; Li WK; Chen FZ; Rao ZZ; Liu XF; Luo YP; Cao YF
Eur J Cancer Prev; 2008 Jun; 17(3):251-8. PubMed ID: 18414197
[TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphisms of CYP2D6, CYP1A1, GSTM1 and p53 genes in a unique Siberian population of Tundra Nentsi.
Duzhak T; Mitrofanov D; Ostashevskii V; Gutkina N; Chasovnikova O; Posukh O; Osipova L; Lyakhovich VV
Pharmacogenetics; 2000 Aug; 10(6):531-7. PubMed ID: 10975607
[TBL] [Abstract][Full Text] [Related]
30. Association of cytochrome P450, glutathione S-transferase and N-acetyl transferase 2 gene polymorphisms with incidence of acute myeloid leukemia.
Majumdar S; Mondal BC; Ghosh M; Dey S; Mukhopadhyay A; Chandra S; Dasgupta UB
Eur J Cancer Prev; 2008 Apr; 17(2):125-32. PubMed ID: 18287869
[TBL] [Abstract][Full Text] [Related]
31. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
Nebert DW; McKinnon RA; Puga A
DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
[TBL] [Abstract][Full Text] [Related]
32. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.
Liou YH; Lin CT; Wu YJ; Wu LS
J Hum Genet; 2006; 51(10):857. PubMed ID: 16924387
[TBL] [Abstract][Full Text] [Related]
33. Xenobiotic sensor- and metabolism-related gene variants in environmental sensitivity-related illnesses: a survey on the Italian population.
Caccamo D; Cesareo E; Mariani S; Raskovic D; Ientile R; Currò M; Korkina L; De Luca C
Oxid Med Cell Longev; 2013; 2013():831969. PubMed ID: 23936614
[TBL] [Abstract][Full Text] [Related]
34. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
[TBL] [Abstract][Full Text] [Related]
35. Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in normal Indians and Malays.
Zhao B; Lee EJ; Wong JY; Yeoh PN; Gong NH
Pharmacogenetics; 1995 Oct; 5(5):275-80. PubMed ID: 8563767
[TBL] [Abstract][Full Text] [Related]
36. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
Skadrić I; Stojković O
Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
[TBL] [Abstract][Full Text] [Related]
37. Genotype frequencies of polymorphic GSTM1, GSTT1, and cytochrome P450 CYP1A1 in Mexicans.
Montero R; Araujo A; Carranza P; Mejía-Loza V; Serrano L; Albores A; Salinas JE; Camacho-Carranza R
Hum Biol; 2007 Jun; 79(3):299-312. PubMed ID: 18078203
[TBL] [Abstract][Full Text] [Related]
38. Inter-ethnic differences in genetic polymorphisms of xenobiotic-metabolizing enzymes (CYP1A1, CYP2D6, NAT1 and NAT2) in healthy populations: correlation with the functional in silico prediction.
Khlifi R; Ben Salah G; Chakroun A; Hamza-Chaffai A; Rebai A
Mol Biol Rep; 2014 Sep; 41(9):5735-43. PubMed ID: 24934312
[TBL] [Abstract][Full Text] [Related]
39. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J
Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072
[TBL] [Abstract][Full Text] [Related]
40. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations.
Zuo J; Xia D; Jia L; Guo T
Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
